Back to today’s briefing

Story perspectives

Novo Nordisk Acquires Akero for Up to $5.2 Billion

10/9/2025

33 2 Full Breakdown

Summary

Story summary

Novo Nordisk to acquire Akero Therapeutics for up to $5.2 billion.
Akero shareholders will receive $54 per share in cash plus up to $6 per share contingent on regulatory approval of efruxifermin by June 2031.
The deal strengthens Novo's liver-disease portfolio, focusing on metabolic dysfunction-associated steatohepatitis (MASH).
Closing is expected by year-end; Mike Doustdar calls it strategically important.

1 of 1

Story summary

Novo Nordisk to acquire Akero Therapeutics for up to $5.2 billion.
Akero shareholders will receive $54 per share in cash plus up to $6 per share contingent on regulatory approval of efruxifermin by June 2031.
The deal strengthens Novo's liver-disease portfolio, focusing on metabolic dysfunction-associated steatohepatitis (MASH).
Closing is expected by year-end; Mike Doustdar calls it strategically important.